Announced Mon, 18 May · 11:33 IST
Please refer attached file
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.2%1-day move
₹174.89
prior close
₹172.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.7+0.8+0.6-1.2+0.7+1.0+0.1+2.5-0.2-3.4-8.2+2.6—
Up moveDown movePending
AI summary
Piramal Pharma has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility in Digwal, Telangana. The inspection has been successfully closed by the US FDA. This follows an earlier notification made on 14th February 2026 regarding the inspection. The EIR was received and the disclosure made on 18th May 2026, which is the first working day after receipt.
Likely market impact
Positive development for the company as successful FDA inspection closure confirms manufacturing compliance and enables continued or expanded operations for US pharmaceutical exports.